Skip to main content
Download PDF

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

BMC Medicine volume 22, Article number: 405 (2024) Cite this article

The Original Article was published on 24 April 2024

Correction: BMC Med 22, 174 (2024)

https://doi.org/10.1186/s12916-024-03389-w


The original article [1] mistakenly omitted Equal Contribution attribution for the first four authors – Ruoshang Han, Haoyue Guo, Jinpeng Shi, and Sha Zhao – due to an error from the production team that handled the manuscript.

The Equal Contribution attribution has since been restored.

Reference

  1. Han R, Guo H, Shi J, et al. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. BMC Med. 2024;22:174. https://doi.org/10.1186/s12916-024-03389-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Ruoshuang Han, Haoyue Guo, Jinpeng Shi and Sha Zhao contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

    Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu & Caicun Zhou

  2. Department of Oncology, The First Affiliated Hospital of Army Medical University, Chongqing, People’s Republic of China

    Ruoshuang Han

  3. Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

    Lei Cheng, Chao Zhao & Xuefei Li

Authors
  1. Ruoshuang Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haoyue Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinpeng Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sha Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yijun Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaozhen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lei Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xuefei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Caicun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caicun Zhou.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, R., Guo, H., Shi, J. et al. Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. BMC Med 22, 405 (2024). https://doi.org/10.1186/s12916-024-03644-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12916-024-03644-0

BMC Medicine

ISSN: 1741-7015

Contact us